A sponsor completes a Phase II oncology trial across three APAC markets. The data is clean, the efficacy signal is real, and the team followed the statistical analysis plan. The clinical study report takes eight weeks to draft. Six weeks after submission, the regulatory authority returns a deficiency notice. Not because the trial failed, but […]